

Martin J S Dyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4805176/publications.pdf>

Version: 2024-02-01

192
papers

15,420
citations

13827

67
h-index

18606

119
g-index

194
all docs

194
docs citations

194
times ranked

16250
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood</i> , 2010, 115, 4393-4402.	0.6	782
2	Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types. <i>Cell</i> , 1999, 96, 35-45.	13.5	656
3	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	0.8	541
4	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	0.6	523
5	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 2688-2698.	0.6	445
6	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2008, 40, 1204-1210.	9.4	329
7	The CAMPATH-1 antigen (CDw52). <i>Tissue Antigens</i> , 1990, 35, 118-127.	1.0	328
8	High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. <i>Blood</i> , 2001, 98, 1721-1726.	0.6	307
9	Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 4403-4413.	0.6	294
10	The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. <i>Blood</i> , 2001, 98, 3413-3420.	0.6	273
11	The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. <i>Blood</i> , 2010, 116, 4578-4587.	0.6	271
12	Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. <i>Leukemia Research</i> , 1998, 22, 185-191.	0.4	262
13	Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. <i>Nature Genetics</i> , 1997, 17, 96-99.	9.4	257
14	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
15	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. <i>Blood</i> , 2007, 109, 271-280.	0.6	227
16	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 1474-1477.	0.6	224
17	Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion. <i>Journal of Clinical Oncology</i> , 2007, 25, 5448-5457.	0.8	224
18	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223

#	ARTICLE	IF	CITATIONS
19	CARD9 Is a Novel Caspase Recruitment Domain-containing Protein That Interacts With BCL10/CLAP and Activates NF- κ B. <i>Journal of Biological Chemistry</i> , 2000, 275, 41082-41086.	1.6	221
20	Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 151-153.	1.2	219
21	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. <i>Blood</i> , 2003, 101, 3109-3117.	0.6	212
22	Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non- \hat{c} high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. <i>Blood</i> , 2010, 115, 5393-5397.	0.6	212
23	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
24	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2003, 101, 4539-4546.	0.6	188
25	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2007, 109, 3451-3461.	0.6	188
26	BCL10 Expression in Normal and Neoplastic Lymphoid Tissue. <i>American Journal of Pathology</i> , 2000, 157, 1147-1154.	1.9	183
27	Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. <i>Oncogene</i> , 2002, 21, 6809-6818.	2.6	183
28	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. <i>Blood</i> , 2005, 105, 4445-4454.	0.6	180
29	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	9.4	166
30	Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18022-18027.	3.3	161
31	BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. <i>Blood</i> , 2011, 117, 7145-7154.	0.6	161
32	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. <i>Journal of Clinical Oncology</i> , 2009, 27, 3346-3353.	0.8	154
33	TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies. <i>Cancer Research</i> , 2005, 65, 11265-11270.	0.4	152
34	High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. <i>Blood</i> , 2003, 101, 2547-2550.	0.6	137
35	Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. <i>Blood</i> , 2005, 106, 3214-3222.	0.6	137
36	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. <i>Blood</i> , 2001, 98, 2837-2844.	0.6	125

#	ARTICLE	IF	CITATIONS
37	Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. <i>Cancer Research</i> , 2006, 66, 6785-6792.	0.4	124
38	p53 Abnormalities in B-Cell Prolymphocytic Leukemia. <i>Blood</i> , 1997, 89, 2015-2023.	0.6	115
39	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. <i>Human Molecular Genetics</i> , 2004, 13, 1827-1837.	1.4	115
40	A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms. <i>PLoS ONE</i> , 2009, 4, e6986.	1.1	115
41	Transcriptional silencing of Polo-like kinase 2(SNK/PLK2)is a frequent event in B-cell malignancies. <i>Blood</i> , 2006, 107, 250-256.	0.6	112
42	BCL10 gene mutation in lymphoma. <i>Blood</i> , 2000, 95, 3885-3890.	0.6	109
43	Biallelic <i>ATM</i> Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 4524-4532.	0.8	109
44	Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. <i>Oncogene</i> , 2003, 22, 2643-2654.	2.6	102
45	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	0.6	100
46	Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2019, 104, e68-e71.	1.7	97
47	ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. <i>British Journal of Haematology</i> , 2013, 163, 139-142.	1.2	93
48	Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 4, 220-227.	2.1	91
49	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1530-1542.	5.1	91
50	Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2319-2326.	0.6	90
51	Barriers to Effective TRAIL-Targeted Therapy of Malignancy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4505-4506.	0.8	89
52	pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1. <i>Trends in Cell Biology</i> , 2011, 21, 20-28.	3.6	89
53	Recurrent CDKN1B (p27) mutations in hairy cell leukemia. <i>Blood</i> , 2015, 126, 1005-1008.	0.6	88
54	Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. <i>Blood</i> , 2001, 98, 3479-3482.	0.6	86

#	ARTICLE	IF	CITATIONS
55	Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. <i>International Journal of Cancer</i> , 2002, 98, 470-474.	2.3	84
56	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	80
57	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3326-3333.	0.6	79
58	Recurrent mutation of <i>JAK3</i> in T-cell prolymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 309-316.	1.5	79
59	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	2.0	79
60	Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 1501-1515.	2.5	78
61	The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. <i>FASEB Journal</i> , 2005, 19, 1187-1189.	0.2	77
62	Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 406-415.	1.5	77
63	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 843-846.	0.6	76
64	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
65	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. <i>Molecular Cancer</i> , 2006, 5, 18.	7.9	74
66	Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18078-18083.	3.3	74
67	Targeting anti-apoptotic BCL2 family proteins in haematological malignancies – from pathogenesis to treatment. <i>British Journal of Haematology</i> , 2017, 178, 364-379.	1.2	74
68	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2010, 95, 1510-1518.	1.7	73
69	Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. <i>Leukemia and Lymphoma</i> , 1990, 2, 179-193.	0.6	67
70	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemia – Susceptibility Loci. <i>American Journal of Human Genetics</i> , 2005, 77, 420-429.	2.6	65
71	Phase I/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lincatutumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	1.2	65
72	TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. <i>British Journal of Haematology</i> , 2007, 139, 568-577.	1.2	64

#	ARTICLE	IF	CITATIONS
73	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 265-273.	1.2	64
74	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	0.6	63
75	Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2003, 101, 2756-2761.	0.6	61
76	Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13485-13490.	3.3	61
77	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.4	60
78	Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. <i>International Journal of Cancer</i> , 2006, 118, 1941-1944.	2.3	59
79	t(6;14)(p22;q32): a new recurrent IGH translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2008, 111, 387-391.	0.6	59
80	Identification of Thr29 as a Critical Phosphorylation Site That Activates the Human Proton Channel Hvcn1 in Leukocytes. <i>Journal of Biological Chemistry</i> , 2010, 285, 5117-5121.	1.6	59
81	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. <i>Cancer Research</i> , 2017, 77, 1097-1107.	0.4	59
82	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	1.2	58
83	Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. <i>Blood</i> , 2010, 115, 1490-1499.	0.6	56
84	Efficacy of Vemurafenib in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 286-288.	13.9	56
85	Chromosomal Translocations Fusing the BCL6 Gene to Different Partner Loci Are Recurrent in Primary Central Nervous System Lymphoma and May Be Associated With Aberrant Somatic Hypermutation or Defective Class Switch Recombination. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 776-782.	0.9	53
86	Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 360-370.	1.2	52
87	IgD class switching: Identification of a novel recombination site in neoplastic and normal B cells. <i>European Journal of Immunology</i> , 1995, 25, 3504-3508.	1.6	51
88	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. <i>Blood</i> , 2012, 120, 3949-3957.	0.6	48
89	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	0.6	48
90	Phase 1b Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46

#	ARTICLE	IF	CITATIONS
91	Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood. <i>Clinical Cancer Research</i> , 2010, 16, 4217-4225.	3.2	45
92	High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 712-726.	1.2	45
93	Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. <i>Blood</i> , 2010, 116, 1317-1320.	0.6	44
94	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 499-507.	1.2	44
95	The BCL7 gene family: deletion of BCL7B in Williams syndrome. <i>Gene</i> , 1998, 224, 35-44.	1.0	43
96	The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. <i>European Journal of Immunology</i> , 1989, 19, 381-388.	1.6	42
97	BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 -938A>C promoter single nucleotide polymorphism. <i>Blood</i> , 2008, 111, 874-877.	0.6	42
98	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016, 7, 11889.	5.8	42
99	No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Selzary syndrome. <i>Blood</i> , 2005, 105, 4148-4149.	0.6	41
100	Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 138, 217-220.	1.2	40
101	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
102	Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial. <i>British Journal of Haematology</i> , 2014, 165, 575-578.	1.2	34
103	ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. <i>Haematologica</i> , 2012, 97, 142-146.	1.7	32
104	Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3088-3097.	1.9	31
105	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	0.6	30
106	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 2150-2163.	1.7	30
107	Persistent polyclonal B-cell lymphocytosis. <i>Leukemia Research</i> , 1994, 18, 791-795.	0.4	29
108	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009, 144, 317-331.	1.2	28

#	ARTICLE	IF	CITATIONS
109	Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2009, 94, 1020-1023.	1.7	28
110	Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 4843-4846.	0.6	27
111	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017, 102, e360-e363.	1.7	27
112	Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 641-651.	1.2	26
113	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. <i>Cancers</i> , 2018, 10, 127.	1.7	26
114	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
115	Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. <i>Leukemia</i> , 1999, 13, 222-229.		24
116	Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 459-464.	0.6	24
117	Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. <i>Human Molecular Genetics</i> , 2010, 19, 1840-1845.	1.4	24
118	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.	1.5	23
119	A multicentre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, relapsed chronic lymphocytic leukaemia or mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 429-433.	1.2	23
120	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015, 126, 494-494.	0.6	23
121	CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 340-348.	1.6	22
122	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	2.5	22
123	Lack of MDM2 amplification in human leukaemia. <i>British Journal of Haematology</i> , 1994, 86, 407-409.	1.2	21
124	The Pathogenetic Role of Oncogenes Deregulated by Chromosomal Translocation in B-Cell Malignancies. <i>International Journal of Hematology</i> , 2003, 77, 315-320.	0.7	21
125	Laparoscopic splenectomy: a personal series of 140 consecutive cases. <i>Annals of the Royal College of Surgeons of England</i> , 2010, 92, 398-402.	0.3	21
126	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. <i>Haematologica</i> , 2017, 102, 765-772.	1.7	21

#	ARTICLE	IF	CITATIONS
127	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	21
128	Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2006, 132, 115-116.	1.2	20
129	Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. <i>British Journal of Haematology</i> , 2009, 146, 384-395.	1.2	20
130	Caspase cleavage of Itch in chronic lymphocytic leukemia cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 379, 659-664.	1.0	20
131	Pituitary infiltration in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 115, 718-718.	1.2	19
132	Report: workshop on mediastinal grey zone lymphoma. <i>European Journal of Haematology</i> , 2005, 75, 45-52.	1.1	19
133	The <i>CBFA2T3/ACSF3</i> locus is recurrently involved in <i>IGH</i> chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 338-343.	1.5	18
134	In Response to Fakruddin et al. and Apostolou et al. <i>Cell</i> , 1999, 97, 686-688.	13.5	17
135	Proteomic analysis of B-cell malignancies. <i>Journal of Proteomics</i> , 2010, 73, 1804-1822.	1.2	17
136	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 309-317.e3.	0.2	17
137	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 344-349.	1.0	16
138	Breaking good: the inexorable rise of <i>BTK</i> inhibitors in the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 12-22.	1.2	15
139	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	1.7	15
140	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15
141	Prdm6 Is Essential for Cardiovascular Development In Vivo. <i>PLoS ONE</i> , 2013, 8, e81833.	1.1	15
142	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2015, 170, 40-49.	1.2	14
143	Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. <i>Haematologica</i> , 2019, 104, 1016-1025.	1.7	14
144	Proteolytic Cleavage of Molecules Involved in Cell Death or Survival Pathways: A Role in the Control of Apoptosis?. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2001, 11, 10.	0.4	14

#	ARTICLE	IF	CITATIONS
145	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13
146	Acute myelomonocytic leukemia with t(10;11)(p13;q23): Heterogeneity of breakpoints at 11q23 and association with recombinase activation. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 136-139.	1.5	12
147	Primary lymphoma-like lesions of the uterine cervix; sheep in wolves'™ clothing. <i>British Journal of Haematology</i> , 2011, 153, 791-794.	1.2	12
148	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 133-145.	1.4	12
149	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study. <i>Haematologica</i> , 2021, 106, 2774-2778.	1.7	12
150	p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 6498-6499.	0.6	11
151	Alemtuzumab-resistant SÅ©zary syndrome responding to zanolimumab*. <i>British Journal of Haematology</i> , 2011, 154, 419-421.	1.2	11
152	Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. <i>British Journal of Haematology</i> , 2013, 160, 725-733.	1.2	11
153	DNA methylation profiling of hepatosplenic T-cell lymphoma. <i>Haematologica</i> , 2019, 104, e104-e107.	1.7	11
154	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 22872-22885.	0.8	11
155	TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. <i>British Journal of Haematology</i> , 2011, 153, 533-535.	1.2	10
156	Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 2561-2562.	0.6	9
157	BCL7A protein expression in normal and malignant lymphoid tissues. <i>British Journal of Haematology</i> , 2013, 160, 106-109.	1.2	9
158	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
159	Characterization of a t(10; 11) (p13-14; q14-21) in the monoblastic cell line U937. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 138-142.	1.5	8
160	Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 525-529.	2.5	8
161	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 199-207.	1.1	7
162	A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of theBCL6andMYCLoci Associated with Good Clinical Outcome. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	7

#	ARTICLE	IF	CITATIONS
163	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.. Blood, 2006, 108, 2719-2719.	0.6	7
164	BCL10 gene mutation in lymphoma. Blood, 2000, 95, 3885-3890.	0.6	7
165	Paradoxical activation of alternative pro-€survival pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 182, 921-924.	1.2	6
166	T-Cell Receptor and Immunoglobulin Gene Rearrangements in Acute Myeloid and Undifferentiated Leukemias of Adults: Correlation with Weak Surface Expression of CD45 and CDw52 Antigens. Leukemia and Lymphoma, 1991, 3, 257-265.	0.6	5
167	Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies. Cancer Genetics and Cytogenetics, 2003, 144, 83-84.	1.0	5
168	Posttranscriptional Upregulation of p53 by Reactive Oxygen Species in Chronic Lymphocytic Leukemia. Cancer Research, 2016, 76, 6311-6319.	0.4	5
169	Monoclonal Antibodies for Immunosuppression. Chemical Immunology and Allergy, 1988, 45, 16-30.	1.7	4
170	Immunoblastic Transformation of a Sezary Syndrome in a Black Caribbean Patient Without Evidence of HTLV-I. Leukemia and Lymphoma, 1995, 18, 521-527.	0.6	4
171	Cloning of Immunoglobulin Chromosomal Translocations by Long-Distance Inverse Polymerase Chain Reaction. , 2005, 115, 217-230.		4
172	Bilateral subdural hygromas following intrathecal methotrexate. British Journal of Haematology, 2011, 155, 536-536.	1.2	4
173	Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion. International Journal of Hematology, 2018, 107, 345-354.	0.7	4
174	The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo. Blood, 2008, 112, 707-707.	0.6	4
175	The Detection of Chromosomal Translocations Involving the Immunoglobulin Loci in B-Cell Malignancies. Methods in Molecular Biology, 2013, 971, 123-133.	0.4	3
176	Differential activation of pro-€survival pathways in response to CD40LG/IL4 stimulation in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2019, 184, 867-869.	1.2	3
177	Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis. Leukemia, 2021, 35, 2407-2411.	3.3	3
178	Proteomic Analysis of Cell Surface Membrane Proteins in Leukemic Cells. Methods in Molecular Biology, 2007, 370, 135-146.	0.4	3
179	Bioweapons of Tumor Mass Destruction?. Journal of Clinical Oncology, 2003, 21, 3011-3012.	0.8	2
180	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica, 2014, 99, 1285-1291.	1.7	2

#	ARTICLE	IF	CITATIONS
181	Monoclonal Antibodies for Immunosuppression. <i>Chemical Immunology and Allergy</i> , 1988, 45, 16-30.	1.7	1
182	Receptor-selective TRAIL Mutants Target Lymphoid Tumor cells for Apoptosis via TRAIL-R1: Implications for Therapy. <i>Toxicology</i> , 2008, 253, 6-7.	2.0	1
183	Identification of Phosphorylation Sites that Activate Voltage Gated Proton Channels in Leukocytes. <i>Biophysical Journal</i> , 2009, 96, 170a-171a.	0.2	1
184	Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation. <i>Leukemia Research</i> , 2011, 35, e55-e57.	0.4	1
185	Chimeric antibodies for the treatment of hematologic malignancy. <i>Cancer Treatment and Research</i> , 1993, 68, 161-180.	0.2	1
186	Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e752.	1.2	1
187	Mature T-cell Malignancies. <i>Human Cell Culture</i> , 2002, , 321-337.	0.1	0
188	David Galton – the thesis years. <i>Leukemia and Lymphoma</i> , 2007, 48, 2290-2291.	0.6	0
189	DAT ± AHA = bad CLL. <i>Blood</i> , 2008, 111, 1757-1757.	0.6	0
190	Ask the Experts: Precision medicines: a new era for the treatment of B-cell malignancies. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 113-116.	0.7	0
191	Chronic lymphocytic leukaemia therapy: is less more?. <i>Lancet Haematology</i> , the, 2022, 9, e169-e171.	2.2	0
192	Proteomic Analysis of Cell Surface Membrane Proteins in Leukemic Cells. , 0, , 135-146.		0